Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting CDK4/6 in patients with cancer.
Hamilton E, Infante JR. Hamilton E, et al. Among authors: infante jr. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Epub 2016 Mar 8. Cancer Treat Rev. 2016. PMID: 27017286 Free article. Review.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Italiano A, et al. Among authors: infante jr. Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076. Ann Oncol. 2018. PMID: 29788155 Free article. Clinical Trial.
Targeting PI3 kinase in cancer.
Bauer TM, Patel MR, Infante JR. Bauer TM, et al. Among authors: infante jr. Pharmacol Ther. 2015 Feb;146:53-60. doi: 10.1016/j.pharmthera.2014.09.006. Epub 2014 Sep 18. Pharmacol Ther. 2015. PMID: 25240910 Review.
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI. Infante JR, et al. Clin Cancer Res. 2016 Dec 1;22(23):5696-5705. doi: 10.1158/1078-0432.CCR-16-1248. Epub 2016 Aug 19. Clin Cancer Res. 2016. PMID: 27542767 Free PMC article. Clinical Trial.
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. Bendell JC, et al. Among authors: infante jr. Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15. Cancer. 2015. PMID: 26177599 Free PMC article. Clinical Trial.
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O. Ott PA, et al. Among authors: infante jr. Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28. Cancer. 2019. PMID: 30690710 Free article. Clinical Trial.
Molecular Pathways: Fatty Acid Synthase.
Jones SF, Infante JR. Jones SF, et al. Among authors: infante jr. Clin Cancer Res. 2015 Dec 15;21(24):5434-8. doi: 10.1158/1078-0432.CCR-15-0126. Epub 2015 Oct 30. Clin Cancer Res. 2015. PMID: 26519059 Review.
221 results